SCHEMBL6486920

SCHEMBL6486920

O=C(NC1CC2CC1CN2)c1ccc(-c2ccccc2NC(=O)C(F)(F)F)o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
LMNA P02545 7/20 0.40
POLB P06746 2/20 0.40
GAA P10253 2/20 0.40
HPGD P15428 5/20 0.39
TDP1 Q9NUW8 4/20 0.39
KDM4E B2RXH2 4/20 0.39
MAPT P10636 6/20 0.39
HTT P42858 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
SMN1; SMN2 Q16637 7/20 0.38
RAB9A P51151 7/20 0.38
HSD17B10 Q99714 4/20 0.38
TSHR P16473 2/20 0.38
ATM Q13315 1/20 0.38
NPC1 O15118 4/20 0.37
KMT2A Q03164 3/20 0.37
PARP14 Q460N5 1/20 0.37
MAPK1 P28482 2/20 0.36
MEN1 O00255 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488018 0.88 ALDH1A1 (0.48) ALDH1A1LMNAGAAHPGDTDP1
SCHEMBL6499550 0.84 MAPKAPK2 (0.41) ALDH1A1LMNAPOLBKDM4EMAPT
SCHEMBL6496470 0.84 FAAH (0.36) MAPTHTTKMT2APARP14MEN1
SCHEMBL6489150 0.83 ALDH1A1 (0.39) ALDH1A1LMNAPOLBGAAHPGD
SCHEMBL6498308 0.83 RAB9A (0.53) ALDH1A1LMNAGAAHPGDTDP1
SCHEMBL6498429 0.82 RAB9A (0.40) ALDH1A1LMNAPOLBGAAHPGD
SCHEMBL6496691 0.82 MAPT (0.40) ALDH1A1LMNAPOLBHPGDTDP1
SCHEMBL6486675 0.81 SLC9A1 (0.44) ALDH1A1LMNAGAAHPGDTDP1
SCHEMBL6497808 0.81 ALDH1A1 (0.54) ALDH1A1LMNAGAAHPGDTDP1
SCHEMBL6488977 0.81 ALDH1A1 (0.53) ALDH1A1LMNAPOLBGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 ALDH1A1 625/4885LMNA 2990/4885POLB 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.